Life sciences software & AI news

Daily news on AI, software, and digital tools for pharma, biotech, CROs, and life sciences research labs.

Showing 1000+ results
Stylized stock market graph silhouette

Jul 22, 2026

Wall Street can wait: Why one U.S. biotech firm is listing in Hong Kong first

Axiom, a U.S. biotech firm, is opting for a Hong Kong listing ahead of a U.S. debut, highlighting a shift in the funding landscape for biotech companies.According to Remo Moomiaie-Qajar, Axiom's CEO, the U.S. biotech funding model has not evolved alongside the industry's needs, prompting firms to explore alternative markets. He noted that recent biotech listings in Hong Kong have outperformed those on the Nasdaq, suggesting a more mature ecosystem in that region. The Hong Kong exchange's stricte
An upward arrow and stock chart silhouette representing stock market gains.

Jul 21, 2026

US Stock Movers: Aehr Test Systems Surges 28% as AI Names Shine; Danaher Slides 11%

US equities experienced significant fluctuations in after-hours trading, with Aehr Test Systems leading the gains, surging nearly 28% to $98.91. The rise was largely driven by heightened interest in AI-related companies, as Nebius Group and Cerebras Systems also saw substantial increases, climbing 18.78% and 17.92% respectively.Other notable gainers included Ouster, which rose 17%, and Regencell Bioscience Holdings, which increased by 18.82%. This trend highlights a robust investor enthusiasm fo
A server rack in a data center with glowing lights and cables

Jul 21, 2026

Pharma Giant and NVIDIA Join Forces to Build the Most Powerful AI Supercomputer Yet

Bristol Myers Squibb (BMS) and NVIDIA are collaborating to create a groundbreaking AI supercomputer aimed at revolutionizing drug development in the pharmaceutical industry.The partnership is set to launch the supercomputer in January 2027, with infrastructure support from Equinix. This initiative reflects a broader trend within the industry as companies increasingly adopt artificial intelligence to enhance drug discovery processes and reduce operational costs. BMS researchers will utilize NVIDI
A vial of biotech compound in a dimly lit lab setting

Jul 21, 2026

Biotech IPOs Surge 55% as AI Listings Lose Momentum

Recent trends in the IPO market reveal a significant surge in biotechnology and pharmaceutical listings, overshadowing the waning momentum of artificial intelligence offerings.As of mid-July, biotech and pharma IPOs have seen a remarkable average return of 55%, starkly contrasting with a 4.4% average loss across the broader U.S. IPO market, excluding special purpose acquisition companies. This upswing comes amid a decline in shares from the largest IPOs of 2026, prompting concerns about an overe
A minimalist illustration of a pill and coins representing biotechnology funding.

Jul 21, 2026

Dimension restocks with $800M to capitalize on AI’s ‘rapid ascent’

Dimension, a venture capital firm focused on integrating artificial intelligence into biotechnology, has successfully raised $800 million for its third fund, "Dimension III."This new funding brings Dimension's total assets under management to $1.65 billion and supports its mission to drive the digitization of drug development. Founded by former partners from Lux Capital and Obvious Ventures, Dimension emphasizes the increasing collaboration between computer scientists and biologists in creating
A syringe on a lab bench with a medical device in the background.

Jul 21, 2026

From Mechanical Precision to Software Intelligence

The future of MedTech may hinge on the evolution from traditional hardware to advanced software platforms that enhance learning and adaptability. The MedTech industry is at a pivotal moment, transitioning from a focus on hardware-centric products to the development of software-enabled platforms. This shift is poised to generate significant benefits, including ongoing value creation, enhanced operational efficiency, accelerated innovation cycles, and improved patient outcomes. Kearney's analysis
A minimalist illustration of a test tube and DNA strand representing health technologies.

Jul 21, 2026

Senate moves to bring IVF, AI diagnostics, GMOs under new regulatory framework

The Nigerian Senate is advancing a significant bill aimed at establishing a comprehensive regulatory framework for emerging health technologies, including in vitro diagnostics, AI-assisted diagnostics, biotechnology, and genetically modified organisms (GMOs).This legislative initiative seeks to repeal outdated laws governing food and drug regulation, replacing them with a unified statute that aligns with global best practices. Senator Suleiman Sadiq, who led the discussion, emphasized that exist
A minimalist illustration of a surgical robot arm with a scalpel in an operating room setting.

Jul 21, 2026

Medtronic adds real-time AI to Hugo robot

Medtronic has unveiled a new application for its Hugo surgical robot that leverages artificial intelligence to enhance decision-making during surgical procedures.The new platform, known as the Touch Surgery Aide, integrates Nvidia's computational resources and features an AI application called Instrument Exit Point (IEP), which has received FDA approval. Medtronic plans to showcase this innovative technology at the Society of Robotic Surgery meeting in Florida.This development marks a significan
A glass vial and clipboard in a clinical office setting

Jul 21, 2026

Mid-Year Check-In: Has Pharma's Commercial Caution Lifted?

The pharmaceutical industry is navigating a landscape of evolving caution and uncertainty as it progresses through 2026, according to insights from Emma Banks, CEO of ramarketing. In a recent update, she reflected on how the anticipated "two halves" of the year have manifested, revealing a more complex narrative of visibility versus uncertainty.Banks noted that while some companies are confidently investing due to strong order books, others are struggling to secure opportunities. This disparity
A minimalist illustration of a pill bottle and a prescription pad on a solid background.

Jul 21, 2026

Inside Semmelweis: Doceree's AI Bet on Pharma Marketing

Doceree has introduced Semmelweis, an AI model tailored for pharmaceutical marketing, which emphasizes clinical context over general-purpose AI approaches.Semmelweis is designed to enhance pharmaceutical commercialization by utilizing Clinical Intent Signals (CIS) that reflect treatment pathways and prescribing behaviors. This model is integrated into Doceree's Daily Command, a commercial operating system aimed at streamlining pharma marketing processes. By leveraging a unique identity graph of
A laboratory flask with a biotech compound in a dimly lit lab setting.

Jul 21, 2026

Biotech IPOs lead 2026 US market, overshadowing AI firms like Anthropic

The biotechnology sector is leading the US IPO market in 2026, significantly outperforming AI firms like Anthropic. With biotech IPOs achieving a 55% average return, they stand in stark contrast to the broader market, which has seen a 4.4% decline.This surge in biotech is reshaping investor sentiment, particularly regarding AI IPOs. Anthropic, for instance, has seen a slight decline in the projected likelihood of its IPO by September 30, 2026, now estimated at 5.5%. This shift suggests that the
Petri dish with cell cultures and research notes in a lab

Jul 21, 2026

Sightera Bio secures €3 million for AI drug discovery platform

Sightera Biosciences has successfully secured €3 million in pre-seed funding to enhance its AI-driven drug discovery platform, focusing on oncology and fibrosis.The Antwerp-based startup plans to utilize this funding to expand its team, advance its technology, and move its lead oncology program toward preclinical candidate selection. Additionally, Sightera aims to strengthen partnerships with pharmaceutical and biotech firms. The funding round was led by Entourage, Anacura, and QBIC, highlightin